Recommended Free Tools
iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
A biotech capital raising can reduce your percentage ownership if the company issues new shares and you do not buy enough of them to keep your stake unchanged. But dilution is not one number: an offering may also report a separate accounting measure called dilution per share, and warrants, options or convertible securities may create additional shares later. To assess the effect, read the share-count assumptions, proceeds, transaction terms and planned use of funds together.
What happens to your ownership when a biotech issues shares?
Your ownership percentage is the number of shares you hold divided by the company’s total shares. If the company issues additional shares and you buy none, your share count stays the same while the denominator grows, so your percentage falls.
For example, if you own 100 shares out of 1,000, you own 10%. If the company issues 250 new shares and you do not participate, you own 100 out of 1,250, or 8%. This is an arithmetic illustration of ownership percentage, not a prediction of the share price or your investment return. If you buy new shares, the resulting percentage depends on how many you can buy and the offering’s eligibility and allocation rules.
Windows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstallOutdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchThe ASX and AusBiotech Guide to life sciences investing identifies public or private share issuance as a form of dilutive financing. Whether existing shareholders can participate depends on the specific offer and applicable jurisdiction; do not assume every capital raising gives them that right.
#1 Best Overall
What does “dilution” mean in an offering document?
Check what the document is measuring. Ownership dilution is the change in your fraction of the company. A prospectus may instead use “dilution” to describe the difference between the offering price and the company’s adjusted net tangible book value per share after the offering. That accounting comparison is not a guaranteed market-price decline and does not, by itself, measure the company’s economic value.
In its 2026 prospectus, BioVie Inc. used an assumed combined offering price of $1.56 per share and accompanying warrant and estimated $22.7 million in net proceeds. Under its stated assumptions, it calculated immediate net tangible book value dilution of $0.17 per share for new investors. These are figures for that issuer and transaction, not a biotech-market average. See the BioVie SEC prospectus for its assumptions and calculation.
A second biotech issuer’s 2026 prospectus described 3,625,000 shares offered at $0.795 each, gross proceeds of $2,881,875, and estimated immediate per-share dilution of $0.80 under its stated net tangible book deficit calculation. Those figures likewise apply only to that issuer’s filing and assumptions. The SEC prospectus supplement explains its calculation.
Which securities could add shares beyond the headline offering?
The shares listed in the headline offer may not be the only securities that can affect future ownership. Read the filing’s share-count table and its assumptions and exclusions. Depending on the issuer and terms, potentially share-creating securities can include:
- Warrants: rights to buy shares under specified terms. BioVie’s cited offering paired shares with accompanying warrants; its filing also warned that exercising outstanding warrants and stock options may further dilute an investment.
- Pre-funded warrants: securities that may be exercisable for shares under the conditions in the filing. Check their specific exercise and ownership terms rather than treating them as ordinary shares.
- Options and restricted stock units: employee or other equity awards that may affect share counts when exercised, settled or vested, subject to their terms.
- Convertible notes: debt that may convert into shares under stated conditions. A second 2026 biotech prospectus identifies convertible notes as well as warrants, options and restricted stock units that could affect future share counts.
These instruments do not all work alike. Their exercise prices, conversion terms, ownership limits and any cash proceeds vary by issuer. A “fully diluted” share count is meaningful only alongside the filing’s definition of what it includes and excludes.
How can the money raised change the impact of dilution?
An offering gives a company capital, but the investor impact depends on more than the number of shares issued. Consider the amount the company actually receives after costs, what the proceeds are intended to fund, the terms of the securities sold and whether the funding helps the business reach meaningful progress.
Rank #4
The ASX and AusBiotech guide states: “If the company is properly funded, the dilution will be outweighed by value creation.” That is a possibility, not a promise: future value creation is uncertain, and the outcome depends on the company’s progress and the price investors paid.
Free tools Windows power users keep installed
One-click scans. No signup required.
Use-of-proceeds language is also a plan, not proof of what will happen. The second 2026 biotech prospectus lists research and development, sales and marketing, administration, working capital and capital expenditures among intended uses, while retaining management discretion and noting future funding needs. BioVie’s filing likewise describes management discretion over proceeds and the possibility of needing additional funding.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What should you check in a capital-raising announcement or prospectus?
- Identify what is being sold. Is it common or ordinary shares, shares with warrants, pre-funded warrants, convertible debt or another security?
- Read the price and proceeds carefully. Compare the offer price and maximum amount with estimated net proceeds, fees and closing conditions. Gross proceeds are not the same as cash the company expects to retain.
- Check how the deal can close. Is it a firm-commitment or best-efforts offering? Is there a minimum amount that must be raised? BioVie’s cited 2026 offering was best efforts and had no minimum proceeds condition; its filing says the issuer could receive significantly less than its estimated proceeds.
- Compare share counts on a consistent basis. Look at shares outstanding before and after the offering under the filing’s assumptions. Note excluded options, warrants, convertible securities and equity awards; do not compare a basic share count with another issuer’s fully diluted count as though they were equivalent.
- Read the proceeds plan and its flexibility. Determine which uses are specified and how much discretion management retains.
- Consider the shortfall scenario. What if the company raises less than planned, spends the proceeds before reaching its goals or needs more cash later? A future financing could bring further dilution or have other consequences, depending on its terms.
- Check participation rights and allocation rules. The offer documents should explain whether existing holders can subscribe and how access is determined. Rights vary by offering and jurisdiction.
How should you compare two biotech offerings?
Compare like with like, using each issuer’s current filings and the same share-count basis. A larger headline offering is not automatically better if it comes with different costs, terms or funding needs.
| What to compare | What to look for |
|---|---|
| Price and size | Offer price, number of securities and maximum gross proceeds. |
| Cash to the issuer | Estimated net proceeds after fees and expenses, and any minimum or closing conditions. |
| Security package | Shares, warrants, pre-funded warrants, convertible securities or other instruments, with their specific terms. |
| Share-count impact | Pre- and post-offering shares on a stated basis, plus potentially dilutive securities included or excluded. |
| Existing-holder access | Subscription rights, eligibility and allocation rules in the specific offer. |
| Use of proceeds | Stated purposes, management discretion and what happens if funding is insufficient. |
| Company financing context | Current scientific and clinical milestones and the funding needed to pursue them, based on current issuer filings. |
The prospectuses cited here are examples, not templates for every biotech financing. Their numerical dilution figures cannot establish whether a particular offer is attractive; that judgment requires current issuer-specific information and valuation work. Securities rules and offering mechanics also vary by country and market.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
The Tool Desk
Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →
